相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
Camelia Quek et al.
Oncotarget (2019)
Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma
Lucas D. Trucco et al.
NATURE MEDICINE (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network
Julie Delyon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets
Jiong Lyu et al.
JOURNAL OF PATHOLOGY (2018)
Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma
Julien Ablain et al.
SCIENCE (2018)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mucosal melanomas in the racially diverse population of California
Lisa Altieri et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma
Jennifer D. Hintzsche et al.
MELANOMA RESEARCH (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
NRAS-mutant melanoma: current challenges and future prospect
Eva Munoz-Couselo et al.
ONCOTARGETS AND THERAPY (2017)
RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma
Coralie Dorard et al.
NATURE COMMUNICATIONS (2017)
Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
Mengdong Liu et al.
ONCOTARGET (2017)
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
Ioana Cosgarea et al.
ONCOTARGET (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey
Lauge H. Mikkelsen et al.
APMIS (2016)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis
Xinan Sheng et al.
EUROPEAN JOURNAL OF CANCER (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi
Oriol Yelamos et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
Deborah Kuk et al.
ONCOLOGIST (2016)
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
Ross A. Okimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Driver KIT mutations in melanoma cluster in four hotspots
Nicolas Dumaz et al.
MELANOMA RESEARCH (2015)
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
John C. Hunter et al.
MOLECULAR CANCER RESEARCH (2015)
Regulation of RAF protein kinases in ERK signalling
Hugo Lavoie et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Melanoma
Dirk Schadendorf et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Rare codons capacitate Kras-driven de novo tumorigenesis
Nicole L. K. Pershing et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis
Kenneth D. Bishop et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract
Diane Tseng et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
Christin E. Burd et al.
CANCER DISCOVERY (2014)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
Simon J. Furney et al.
JOURNAL OF PATHOLOGY (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2013)
NMR-based functional profiling of RASopathies and oncogenic RAS mutations
Matthew J. Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Sunitinib Therapy for Melanoma Patients with KIT Mutations
David R. Minor et al.
CLINICAL CANCER RESEARCH (2012)
Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si et al.
EUROPEAN JOURNAL OF CANCER (2012)
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Jin Hyun Cho et al.
INVESTIGATIONAL NEW DRUGS (2012)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Michael Krauthammer et al.
NATURE GENETICS (2012)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Raf kinases in cancer-roles and therapeutic opportunities
G. Maurer et al.
ONCOGENE (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
BRAF Inactivation Drives Aneuploidy by Deregulating CRAF
Tamihiro Kamata et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. M. Smalley et al.
ONCOGENE (2009)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2008)
Ras oncogenes: split personalities
Antoine E. Karnoub et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
Anton Platz et al.
MOLECULAR ONCOLOGY (2008)
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf
Greg Buhrman et al.
STRUCTURE (2007)
GEFs and GAPs: Critical elements in the control of small G proteins
Johannes L. Bos et al.
CELL (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
MJ Garnett et al.
MOLECULAR CELL (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
分享论文
